{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:59:36Z","timestamp":1793131176377,"version":"4.5.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH102215"],"award-info":[{"award-number":["R01 MH102215"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01 MH105571-01"],"award-info":[{"award-number":["R01 MH105571-01"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s11126-017-9521-z","type":"journal-article","created":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T22:36:01Z","timestamp":1498084561000},"page":"157-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clozapine in Reducing Aggression and Violence in Forensic Populations"],"prefix":"10.1007","volume":"89","author":[{"given":"Kathleen","family":"Patchan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann L.","family":"Hackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Mackowick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond C.","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikwunga","family":"Wonodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MacKenzie A.","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Glassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"9521_CR1","first-page":"3111","volume":"11","author":"B Bortolato","year":"2015","unstructured":"Bortolato, B, Miskowiak, KW, Kohler, CA, et al. Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses. Neuropsychiatr Dis Treat 2015;11:3111\u20133125.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Suppl 1","key":"9521_CR2","first-page":"38","volume":"19","author":"M Carbon","year":"2014","unstructured":"Carbon, M and Correll, CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr 2014;19 Suppl 1:38\u201352; quiz 35\u201337, 53.","journal-title":"CNS Spectr"},{"key":"9521_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/NMD.0000000000000323","volume":"203","author":"PH Lysaker","year":"2015","unstructured":"Lysaker, PH, Vohs, J, Minor, KS, et al. Metacognitive Deficits in Schizophrenia: Presence and Associations With Psychosocial Outcomes. J Nerv Ment Dis 2015;203:530\u2013536.","journal-title":"J Nerv Ment Dis"},{"key":"9521_CR4","first-page":"2125","volume":"11","author":"C Bouwmans","year":"2015","unstructured":"Bouwmans, C, de Sonneville, C, Mulder, CL, et al. Employment and the associated impact on quality of life in people diagnosed with schizophrenia. Neuropsychiatr Dis Treat 2015;11:2125\u20132142.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"9521_CR5","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1176\/appi.ps.52.10.1358","volume":"52","author":"JS Brekke","year":"2001","unstructured":"Brekke, JS, Prindle, C, Bae, SW, et al. Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv 2001;52:1358\u20131366.","journal-title":"Psychiatr Serv"},{"key":"9521_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2147\/NDT.S68321","volume":"10","author":"K Latalova","year":"2014","unstructured":"Latalova, K, Kamaradova, D, and Prasko, J. Violent victimization of adult patients with severe mental illness: a systematic review. Neuropsychiatr Dis Treat 2014;10:1925\u20131939.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"9521_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000120","volume":"6","author":"S Fazel","year":"2009","unstructured":"Fazel, S, Gulati, G, Linsell, L, et al. Schizophrenia and violence: systematic review and meta-analysis. PLoS Med 2009;6:e1000120.","journal-title":"PLoS Med"},{"key":"9521_CR8","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","volume":"264","author":"DA Regier","year":"1990","unstructured":"Regier, DA, Farmer, ME, Rae, DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511\u20132518.","journal-title":"JAMA"},{"key":"9521_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1176\/appi.ps.201400413","volume":"66","author":"KT Mueser","year":"2015","unstructured":"Mueser, KT, Penn, DL, Addington, J, et al. The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. Psychiatr Serv 2015;66:680\u2013690.","journal-title":"Psychiatr Serv"},{"key":"9521_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1176\/appi.ps.201400281","volume":"66","author":"LB Dixon","year":"2015","unstructured":"Dixon, LB, Goldman, HH, Bennett, ME, et al. Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program. Psychiatr Serv 2015;66:691\u2013698.","journal-title":"Psychiatr Serv"},{"key":"9521_CR11","unstructured":"Miami-Dade County Criminal Mental Health Project. [cited 2016 9\/7]; Available from: http:\/\/www.jud11.flcourts.org\/Criminal-Mental-Health-Project ."},{"key":"9521_CR12","unstructured":"Weinstein, H, Kim, D, Mack, A, et al. Prevalence and assessment of mental disorders in correctional settings. Handbook of correctional mental health 2005;43\u201368."},{"key":"9521_CR13","volume-title":"Mental health problems of prison and jail inmates (Bureau of Justice Statistics Special Report, NCJ 213600)","author":"D James","year":"2006","unstructured":"James, D and Glaze, L. Mental health problems of prison and jail inmates (Bureau of Justice Statistics Special Report, NCJ 213600). Washington, DC: Department of Justice 2006;"},{"key":"9521_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00406-004-0495-0","volume":"254","author":"M Soyka","year":"2004","unstructured":"Soyka, M, Morhart-Klute, V, and Schoech, H. Delinquency and criminal offenses in former schizophrenic inpatients 7\u201312 years following discharge. Eur Arch Psychiatry Clin Neurosci 2004;254:289\u2013294.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"9521_CR15","first-page":"7","volume":"7","author":"A Ghoreishi","year":"2015","unstructured":"Ghoreishi, A, Kabootvand, S, Zangani, E, et al. Prevalence and attributes of criminality in patients with schizophrenia. J Inj Violence Res 2015;7:7\u201312.","journal-title":"J Inj Violence Res"},{"key":"9521_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-244X-10-11","volume":"10","author":"H Ascher-Svanum","year":"2010","unstructured":"Ascher-Svanum, H, Nyhuis, AW, Faries, DE, et al. Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia. BMC Psychiatry 2010;10:11.","journal-title":"BMC Psychiatry"},{"key":"9521_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10597-010-9362-9","volume":"47","author":"G Greenberg","year":"2011","unstructured":"Greenberg, G, Rosenheck, RA, Erickson, SK, et al. Criminal justice system involvement among people with schizophrenia. Community Ment Health J 2011;47:727\u2013736.","journal-title":"Community Ment Health J"},{"key":"9521_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1176\/appi.ajp.2008.08030416","volume":"166","author":"J Baillargeon","year":"2009","unstructured":"Baillargeon, J, Binswanger, IA, Penn, JV, et al. Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 2009;166:103\u2013109.","journal-title":"Am J Psychiatry"},{"key":"9521_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1176\/ps.2009.60.6.761","volume":"60","author":"HJ Steadman","year":"2009","unstructured":"Steadman, HJ, Osher, FC, Robbins, PC, et al. Prevalence of serious mental illness among jail inmates. Psychiatr Serv 2009;60:761\u2013765.","journal-title":"Psychiatr Serv"},{"key":"9521_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(02)07740-1","volume":"359","author":"S Fazel","year":"2002","unstructured":"Fazel, S and Danesh, J. Serious mental disorder in 23000 prisoners: a systematic review of 62 surveys. Lancet 2002;359:545\u2013550.","journal-title":"Lancet"},{"key":"9521_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1176\/appi.ps.201000505","volume":"63","author":"WB Hawthorne","year":"2012","unstructured":"Hawthorne, WB, Folsom, DP, Sommerfeld, DH, et al. Incarceration among adults who are in the public mental health system: rates, risk factors, and short-term outcomes. Psychiatr Serv 2012;63:26\u201332.","journal-title":"Psychiatr Serv"},{"key":"9521_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3111\/13696998.2014.971161","volume":"18","author":"I Lin","year":"2015","unstructured":"Lin, I, Muser, E, Munsell, M, et al. Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis. J Med Econ 2015;18:219\u2013229.","journal-title":"J Med Econ"},{"key":"9521_CR23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1176\/appi.ps.201300044","volume":"65","author":"AG Robertson","year":"2014","unstructured":"Robertson, AG, Swanson, JW, Frisman, LK, et al. Patterns of justice involvement among adults with schizophrenia and bipolar disorder: key risk factors. Psychiatr Serv 2014;65:931\u2013938.","journal-title":"Psychiatr Serv"},{"key":"9521_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1176\/appi.ps.201500134","volume":"66","author":"AG Robertson","year":"2015","unstructured":"Robertson, AG, Swanson, JW, Lin, H, et al. Influence of Criminal Justice Involvement and Psychiatric Diagnoses on Treatment Costs Among Adults With Serious Mental Illness. Psychiatr Serv 2015;66:907\u2013909.","journal-title":"Psychiatr Serv"},{"key":"9521_CR25","unstructured":"Love, RC, Kelly, DL, Freudenreich, O, et al. Clozapine underutilization: Addressing the barriers. National Association of State Mental Health Porgram Directors 2016 [cited 2016 October 4]; Available from: http:\/\/www.nasmhpd.org\/sites\/default\/files\/Assessment%201_Clozapine%20Underutilization.pdf ."},{"key":"9521_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane, J, Honigfeld, G, Singer, J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789\u2013796.","journal-title":"Arch Gen Psychiatry"},{"key":"9521_CR27","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","volume":"156","author":"K Wahlbeck","year":"1999","unstructured":"Wahlbeck, K, Cheine, M, Essali, A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990\u2013999.","journal-title":"Am J Psychiatry"},{"key":"9521_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","volume":"158","author":"M Chakos","year":"2001","unstructured":"Chakos, M, Lieberman, J, Hoffman, E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518\u2013526.","journal-title":"Am J Psychiatry"},{"key":"9521_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0920-9964(01)00212-2","volume":"56","author":"A Tuunainen","year":"2002","unstructured":"Tuunainen, A, Wahlbeck, K, and Gilbody, S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56:1\u201310.","journal-title":"Schizophr Res"},{"key":"9521_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12888-014-0253-4","volume":"14","author":"D Sinclair","year":"2014","unstructured":"Sinclair, D and Adams, CE. Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry 2014;14:253.","journal-title":"BMC Psychiatry"},{"key":"9521_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1517\/14656566.2011.626769","volume":"13","author":"L Citrome","year":"2012","unstructured":"Citrome, L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother 2012;13:1545\u20131573.","journal-title":"Expert Opin Pharmacother"},{"key":"9521_CR32","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951\u2013962.","journal-title":"Lancet"},{"key":"9521_CR33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1017\/S146114571100201X","volume":"15","author":"C Frogley","year":"2012","unstructured":"Frogley, C, Taylor, D, Dickens, G, et al. A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol 2012;15:1351\u20131371.","journal-title":"Int J Neuropsychopharmacol"},{"key":"9521_CR34","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1176\/appi.ps.52.11.1510","volume":"52","author":"L Citrome","year":"2001","unstructured":"Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001;52:1510\u20131514.","journal-title":"Psychiatr Serv"},{"key":"9521_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","volume":"159","author":"J Volavka","year":"2002","unstructured":"Volavka, J, Czobor, P, Sheitman, B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255\u2013262.","journal-title":"Am J Psychiatry"},{"key":"9521_CR36","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/JCP.0b013e3181855cd6","volume":"28","author":"MI Krakowski","year":"2008","unstructured":"Krakowski, MI, Czobor, P, and Nolan, KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol 2008;28:485\u2013493.","journal-title":"J Clin Psychopharmacol"},{"key":"9521_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1176\/appi.neuropsych.13110335","volume":"26","author":"J Victoroff","year":"2014","unstructured":"Victoroff, J, Coburn, K, Reeve, A, et al. Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci 2014;26:283\u2013312.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"9521_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan, RW, Kreyenbuhl, J, Kelly, DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71\u201393.","journal-title":"Schizophr Bull"},{"key":"9521_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1017\/S1092852915000784","volume":"21","author":"K Stone-Brown","year":"2016","unstructured":"Stone-Brown, K, Naji, M, Francioni, A, et al. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital. CNS Spectr 2016;21:60\u201369.","journal-title":"CNS Spectr"},{"key":"9521_CR40","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/2045125315581996","volume":"5","author":"I Qurashi","year":"2015","unstructured":"Qurashi, I, Stephenson, P, Chu, S, et al. An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service. Ther Adv Psychopharmacol 2015;5:146\u2013150.","journal-title":"Ther Adv Psychopharmacol"},{"key":"9521_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1258\/rsmmsl.44.3.213","volume":"44","author":"H Smith","year":"2004","unstructured":"Smith, H and White, T. The effect of clozapine on the social behaviour schedule in patients attending a forensic psychiatry day hospital. Med Sci Law 2004;44:213\u2013216.","journal-title":"Med Sci Law"},{"key":"9521_CR42","doi-asserted-by":"publisher","first-page":"767","DOI":"10.4088\/JCP.v61n1009","volume":"61","author":"CA Buscema","year":"2000","unstructured":"Buscema, CA, Abbasi, QA, Barry, DJ, et al. An algorithm for the treatment of schizophrenia in the correctional setting: the Forensic Algorithm Project. J Clin Psychiatry 2000;61:767\u2013783.","journal-title":"J Clin Psychiatry"},{"key":"9521_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/00048670701787529","volume":"42","author":"A Martin","year":"2008","unstructured":"Martin, A, O'Driscoll, C, and Samuels, A. Clozapine use in a forensic population in a New South Wales prison hospital. Aust N Z J Psychiatry 2008;42:141\u2013146.","journal-title":"Aust N Z J Psychiatry"},{"key":"9521_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/acps.12416","volume":"132","author":"KJ Ronaldson","year":"2015","unstructured":"Ronaldson, KJ, Fitzgerald, PB, and McNeil, JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 2015;132:231\u2013240.","journal-title":"Acta Psychiatr Scand"},{"key":"9521_CR45","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijcard.2014.07.103","volume":"176","author":"M Alawami","year":"2014","unstructured":"Alawami, M, Wasywich, C, Cicovic, A, et al. A systematic review of clozapine induced cardiomyopathy. Int J Cardiol 2014;176:315\u2013320.","journal-title":"Int J Cardiol"},{"key":"9521_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40263-014-0222-y","volume":"29","author":"AM Williams","year":"2015","unstructured":"Williams, AM and Park, SH. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs 2015;29:101\u2013111.","journal-title":"CNS Drugs"},{"issue":"Suppl 3","key":"9521_CR47","first-page":"3","volume":"59","author":"G Honigfeld","year":"1998","unstructured":"Honigfeld, G, Arellano, F, Sethi, J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59 Suppl 3:3\u20137.","journal-title":"J Clin Psychiatry"},{"key":"9521_CR48","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1192\/bjp.175.6.576","volume":"175","author":"J Munro","year":"1999","unstructured":"Munro, J, O'Sullivan, D, Andrews, C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. The British Journal of Psychiatry 1999;175:576\u2013580.","journal-title":"The British Journal of Psychiatry"},{"key":"9521_CR49","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4088\/JCP.11m07244","volume":"73","author":"L Lahdelma","year":"2012","unstructured":"Lahdelma, L and Appelberg, B. Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted. J Clin Psychiatry 2012;73:837\u2013842.","journal-title":"J Clin Psychiatry"},{"key":"9521_CR50","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1039856213491990","volume":"21","author":"L Drew","year":"2013","unstructured":"Drew, L. Clozapine and agranulocytosis: re-assessing the risks. Australas Psychiatry 2013;21:335\u2013337.","journal-title":"Australas Psychiatry"},{"key":"9521_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/YIC.0000000000000060","volume":"30","author":"MV Balda","year":"2015","unstructured":"Balda, MV, Garay, OU, Papale, RM, et al. Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012). Int Clin Psychopharmacol 2015;30:109\u2013114.","journal-title":"Int Clin Psychopharmacol"},{"key":"9521_CR52","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1S117","volume":"47","author":"S Ikai","year":"2013","unstructured":"Ikai, S, Suzuki, T, Uchida, H, et al. Reintroduction of clozapine after perforation of the large intestine--a case report and review of the literature. Ann Pharmacother 2013;47:e31.","journal-title":"Ann Pharmacother"},{"key":"9521_CR53","volume-title":"Payne, GF, et al","author":"DL Kelly","year":"2015","unstructured":"Kelly, DL, Ben-Yoav, H, Payne, GF, et al. Blood Draw Barriers for Treatment with Clozapine and Development of Point-of-Care Monitoring Device. Clin Schizophr Relat Psychoses 2015;"},{"key":"9521_CR54","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/acps.12193","volume":"130","author":"S Gee","year":"2014","unstructured":"Gee, S, Vergunst, F, Howes, O, et al. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014;130:16\u201324.","journal-title":"Acta Psychiatr Scand"},{"key":"9521_CR55","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/2045125314566808","volume":"5","author":"TE Tungaraza","year":"2015","unstructured":"Tungaraza, TE and Farooq, S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol 2015;5:88\u201396.","journal-title":"Ther Adv Psychopharmacol"},{"key":"9521_CR56","unstructured":"NC Division of Mental Health, Developmental Disabilities and Substance Abuse Services and the North Carolina Psychiatric Association. Clozapine (Clozaril): an underutilized evidence based treatment [PowerPoint Slides] (n.d.). Retrieved from http:\/\/naminc.org\/nn\/0910Conf\/clozapineresearch.pdf ."},{"key":"9521_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3371\/CSRP.HIFR.01062013","volume":"6","author":"M Hill","year":"2013","unstructured":"Hill, M and Freudenreich, O. Clozapine: key discussion points for prescribers. Clin Schizophr Relat Psychoses 2013;6:177\u2013185.","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"9521_CR58","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2165\/11596930-000000000-00000","volume":"25","author":"L Citrome","year":"2011","unstructured":"Citrome, L and Volavka, J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs 2011;25:1009\u20131021.","journal-title":"CNS Drugs"},{"key":"9521_CR59","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.4088\/JCP.v67n0911","volume":"67","author":"DL Kelly","year":"2006","unstructured":"Kelly, DL, Dixon, LB, Kreyenbuhl, JA, et al. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. J Clin Psychiatry 2006;67:1404\u20131411.","journal-title":"J Clin Psychiatry"},{"key":"9521_CR60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1176\/appi.ps.57.1.133","volume":"57","author":"JB Mallinger","year":"2006","unstructured":"Mallinger, JB, Fisher, SG, Brown, T, et al. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006;57:133\u2013136.","journal-title":"Psychiatr Serv"},{"key":"9521_CR61","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1176\/appi.ajp.160.10.1817","volume":"160","author":"LA Copeland","year":"2003","unstructured":"Copeland, LA, Zeber, JE, Valenstein, M, et al. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry 2003;160:1817\u20131822.","journal-title":"Am J Psychiatry"},{"key":"9521_CR62","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/schbul\/sbl068","volume":"33","author":"DL Kelly","year":"2007","unstructured":"Kelly, DL, Kreyenbuhl, J, Dixon, L, et al. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 2007;33:1221\u20131224.","journal-title":"Schizophr Bull"},{"key":"9521_CR63","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/10401239509149622","volume":"7","author":"FG Moeller","year":"1995","unstructured":"Moeller, FG, Chen, YW, Steinberg, JL, et al. Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann Clin Psychiatry 1995;7:167\u2013173.","journal-title":"Ann Clin Psychiatry"},{"key":"9521_CR64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1600-0447.2011.01776.x","volume":"125","author":"NB Pai","year":"2012","unstructured":"Pai, NB and Vella, SC. Reason for clozapine cessation. Acta Psychiatr Scand 2012;125:39\u201344.","journal-title":"Acta Psychiatr Scand"},{"key":"9521_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/lc.1999.v133.a94931","volume":"133","author":"TB Haddy","year":"1999","unstructured":"Haddy, TB, Rana, SR, and Castro, O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999;133:15\u201322.","journal-title":"J Lab Clin Med"},{"key":"9521_CR66","first-page":"3","volume":"9","author":"S Denic","year":"2009","unstructured":"Denic, S, Showqi, S, Klein, C, et al. Prevalence, phenotype and inheritance of benign neutropenia in Arabs. BMC Blood Disord 2009;9:3.","journal-title":"BMC Blood Disord"},{"key":"9521_CR67","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-0609.1988.tb01192.x","volume":"41","author":"Y Shoenfeld","year":"1988","unstructured":"Shoenfeld, Y, Alkan, ML, Asaly, A, et al. Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Haematol 1988;41:273\u2013277.","journal-title":"Eur J Haematol"},{"key":"9521_CR68","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00439-011-1103-9","volume":"131","author":"DR Crosslin","year":"2012","unstructured":"Crosslin, DR, McDavid, A, Weston, N, et al. Genetic variants associated with the white blood cell count in 13,923 subjects in the eMERGE Network. Hum Genet 2012;131:639\u2013652.","journal-title":"Hum Genet"},{"key":"9521_CR69","first-page":"625","volume":"13","author":"Z Paz","year":"2011","unstructured":"Paz, Z, Nails, M, and Ziv, E. The genetics of benign neutropenia. Isr Med Assoc J 2011;13:625\u2013629.","journal-title":"Isr Med Assoc J"},{"key":"9521_CR70","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ajhg.2007.09.003","volume":"82","author":"MA Nalls","year":"2008","unstructured":"Nalls, MA, Wilson, JG, Patterson, NJ, et al. Admixture mapping of white cell count: genetic locus responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am J Hum Genet 2008;82:81\u201387.","journal-title":"Am J Hum Genet"},{"key":"9521_CR71","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature09534","volume":"467","author":"GR Abecasis","year":"2010","unstructured":"Abecasis, GR, Altshuler, D, Auton, A, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061\u20131073.","journal-title":"Nature"},{"key":"9521_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000360","volume":"5","author":"D Reich","year":"2009","unstructured":"Reich, D, Nalls, MA, Kao, WH, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet 2009;5:e1000360.","journal-title":"PLoS Genet"},{"key":"9521_CR73","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/MOH.0000000000000007","volume":"21","author":"CF Thobakgale","year":"2014","unstructured":"Thobakgale, CF and Ndung'u, T. Neutrophil counts in persons of African origin. Curr Opin Hematol 2014;21:50\u201357.","journal-title":"Curr Opin Hematol"},{"key":"9521_CR74","first-page":"253","volume":"27","author":"KM Patchan","year":"2015","unstructured":"Patchan, KM, Richardson, C, Vyas, G, et al. The risk of suicide after clozapine discontinuation: Cause for concern. Ann Clin Psychiatry 2015;27:253\u2013256.","journal-title":"Ann Clin Psychiatry"},{"key":"9521_CR75","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/schbul\/21.4.579","volume":"21","author":"RW Buchanan","year":"1995","unstructured":"Buchanan, RW. Clozapine: efficacy and safety. Schizophr Bull 1995;21:579\u2013591.","journal-title":"Schizophr Bull"},{"key":"9521_CR76","first-page":"260","volume":"24","author":"RL Borison","year":"1988","unstructured":"Borison, RL, Diamond, BI, Sinha, D, et al. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988;24:260\u2013263.","journal-title":"Psychopharmacol Bull"},{"key":"9521_CR77","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/schbul\/22.4.591","volume":"22","author":"TM Shiovitz","year":"1996","unstructured":"Shiovitz, TM, Welke, TL, Tigel, PD, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22:591\u2013595.","journal-title":"Schizophr Bull"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11126-017-9521-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-017-9521-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-017-9521-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T19:06:44Z","timestamp":1659121604000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11126-017-9521-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["9521"],"URL":"https:\/\/doi.org\/10.1007\/s11126-017-9521-z","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]},"assertion":[{"value":"22 June 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported in part by grants NIMH R01 MH102215 (Kelly PI) and R01 MH105571\u201301 (Kelly PI).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Raymond Love owns stock in GlaxoSmithKline. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of Potential Conflicts of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}}]}}